Product Information
MEMANTINE HCL ER 21 MG CAPSULE is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.3563 per EA under NDC 16571085403. Its NADAC has been published 36 times since Jan 28, 2026.
FDA first approved this application on Sep 28, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the memantine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
21 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
16571085403
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MEMANTINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA206032FDA Approved
9/28/2016
TE Code
AB
On Market Since
6/1/2025
Pharmacological Classes
Price Statistics
The NADAC for MEMANTINE HCL ER 21 MG CAPSULE has been published 36 times since Jan 28, 2026, and over the history we have for it it has risen 12.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3563 per EA |
|---|---|
| All-time high | $0.3585 (May 13, 2026) |
| All-time low | $0.3112 (Jul 22, 2026) |
| 52-week high | $0.3585 |
| 52-week low | $0.3112 |
| Median price | $0.3323 |
| Average price | $0.3349 |
| Largest weekly change | +9.8% (Sep 23, 2026) |
| Weeks tracked | 36 |
| Tracking since | Jan 28, 2026 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the memantine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
memantine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
N-methyl-D-aspartate Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MEMANTINE HCL ER 21 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for MEMANTINE HCL ER 21 MG CAPSULE, manufactured by Rising Pharma Holdings Inc., is $0.3563 per EA (NDC 16571085403), effective Sep 30, 2026.
How has the price of MEMANTINE HCL ER 21 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for MEMANTINE HCL ER 21 MG CAPSULE has risen 12.2%. It has been tracked across 36 weekly CMS publications since Jan 28, 2026.
What are the highest and lowest recorded NADAC prices for MEMANTINE HCL ER 21 MG CAPSULE?
Since Jan 28, 2026, the NADAC for MEMANTINE HCL ER 21 MG CAPSULE has ranged from a low of $0.3112 (Jul 22, 2026) to a high of $0.3585 (May 13, 2026), with a median of $0.3323 per EA.
Are there cheaper alternatives to MEMANTINE HCL ER 21 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of MEMANTINE HCL ER 21 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures MEMANTINE HCL ER 21 MG CAPSULE?
MEMANTINE HCL ER 21 MG CAPSULE (NDC 16571085403) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.